Crinetics Pharmaceuticals, Inc. Operating Income

Quick Answer

Crinetics Pharmaceuticals, Inc. reported Operating Income of -$516.77 million for fiscal year 2025.

Crinetics Pharmaceuticals, Inc. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$516.77M -52.5%
2024 -$338.85M -52.2%
2023 -$222.61M -32.6%
2022 -$167.88M -55.9%
2021 -$107.70M -43.7%
2020 -$74.95M -39.2%
2019 -$53.83M -87.5%
2018 -$28.71M -214.6%
2017 -$9.13M -51.0%
2016 -$6.04M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 -$142.59M -62.4% -10.4%
June 30, 2025 -$129.11M -56.0% -15.9%
March 31, 2025 -$111.41M -51.5% -26.9%
September 30, 2024 -$87.80M -48.9% -6.1%
June 30, 2024 -$82.78M -56.2% -12.6%
March 31, 2024 -$73.53M -53.3% -24.7%
September 30, 2023 -$58.98M -35.7% -11.3%
June 30, 2023 -$52.99M -23.1% -10.5%
  • Crinetics Pharmaceuticals, Inc. showed a decrease of -52.5% in Operating Income compared to the prior fiscal year.
  • Over the 2016–2025 period, Crinetics Pharmaceuticals, Inc.’s operating income has declined by 8450.1% (from -$6.04 million to -$516.77 million).
  • The most recent figure is from Crinetics Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment